Boston Scientific BSX is slated to report fourth-quarter fiscal 2024 results on Feb. 5 before market open. See the Zacks Earnings Calendar to stay ahead of market-making news. For fourth-quarter ...

TD Cowen reiterated a Buy rating for Boston Scientific (NYSE:BSX) stock, maintaining a price target of $110.00. The stock, currently trading at $98.78, has shown remarkable momentum, reaching new ...

Boston Scientific’s BSX robust expansion of operations ... The company’s Electrophysiology (EP) arm continues to gain momentum on the sustained adoption of FARAPULSE PFA.

WATCHMAN, a Long-Term Growth Driver: Boston Scientific’s structural heart programs are fast building momentum, banking on a strong performance of the WATCHMAN left atrial appendage closure device.

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you ...

Key barriers in adhering to anticoagulation guidelines included uncertainty about its choice, established practices, and the ...

Marcus projects Boston Scientific (NYSE:BSX) to continue its winning streak of beats and raises this year, thanks to improved margins and momentum in the company’s cardiac devices. PFA (pulse ...

This comes largely from a D- in Momentum and D in Risk, countered by A in Expenses, A+ Dividends and Liquidity.

Crunchy mom influencers often speak with an authority that comes not necessarily from scientific rigor but ... strong health freedom component, gained momentum in the 2010s, as pushback over ...

Shanghai ranks among the world's top 10 innovation cities, alongside other cities from the United States, Britain and Japan, ...

BEIJING -- Beijing, Shanghai and Hong Kong rank among the world's top 10 innovation cities, alongside other cities from the ...

New data shows a “significant decrease” in opioid-related overdose deaths from May to August 2024 when compared to the same ...